Cytosorbents Corp (NASDAQ:CTSO)’s stock price shot up 0.3% during trading on Monday . The company traded as high as $7.10 and last traded at $7.05, 3,117 shares traded hands during trading. A decline of 97% from the average session volume of 106,325 shares. The stock had previously closed at $7.03.
A number of research firms have recently commented on CTSO. ValuEngine raised shares of VESTAS WIND SYS/ADR from a “hold” rating to a “buy” rating in a report on Thursday, May 9th. Maxim Group set a $7.00 price objective on shares of Eagle Bulk Shipping and gave the stock a “buy” rating in a report on Wednesday, May 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. Cytosorbents presently has a consensus rating of “Hold” and an average target price of $14.67.
The stock has a market cap of $222.85 million, a price-to-earnings ratio of -12.59 and a beta of 1.50. The company has a current ratio of 3.70, a quick ratio of 3.52 and a debt-to-equity ratio of 0.62. The company has a 50-day moving average price of $6.53.
Cytosorbents (NASDAQ:CTSO) last announced its earnings results on Tuesday, May 7th. The medical research company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.03. The business had revenue of $5.19 million during the quarter, compared to analysts’ expectations of $6.03 million. Cytosorbents had a negative net margin of 83.93% and a negative return on equity of 103.90%. Analysts predict that Cytosorbents Corp will post -0.56 earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers increased its position in shares of Cytosorbents by 11.7% during the 1st quarter. Rhumbline Advisers now owns 42,589 shares of the medical research company’s stock worth $322,000 after purchasing an additional 4,454 shares in the last quarter. Bank of New York Mellon Corp increased its position in Cytosorbents by 2.7% in the 4th quarter. Bank of New York Mellon Corp now owns 97,330 shares of the medical research company’s stock valued at $786,000 after acquiring an additional 2,516 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its position in Cytosorbents by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 10,442 shares of the medical research company’s stock valued at $84,000 after acquiring an additional 8,155 shares in the last quarter. Skylands Capital LLC increased its position in Cytosorbents by 28.3% in the 1st quarter. Skylands Capital LLC now owns 636,050 shares of the medical research company’s stock valued at $4,815,000 after acquiring an additional 140,200 shares in the last quarter. Finally, Two Sigma Investments LP increased its position in Cytosorbents by 144.8% in the 4th quarter. Two Sigma Investments LP now owns 33,545 shares of the medical research company’s stock valued at $271,000 after acquiring an additional 19,843 shares in the last quarter. Institutional investors and hedge funds own 26.39% of the company’s stock.
Cytosorbents Company Profile (NASDAQ:CTSO)
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Recommended Story: Ex-Dividend
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.